Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study

Yogesh Sharma 1,2, Chris Horwood,3 Paul Hakendorf 1,3 Campbell Thompson4

Objectives Up to 50% of heart failure (HF) patients may be frail and have worse clinical outcomes than non-frail patients. The benefits of HF-specific pharmacotherapy (beta-blockers, ACE-inhibitors/angiotensin-receptor-blockers and mineralocorticoid-receptor-antagonist) in this population are unclear. This study explored whether HF-specific pharmacotherapy improves outcomes in frail hospitalised HF patients.

Design Observational, multicentre, cross-sectional study.

Participants One thousand four hundred and six hospitalised frail HF patients admitted between 1 January 2013 and 31 December 2020.

Measures The Hospital Frailty Risk Score (HFRS) determined frailty status and patients with HFRS ≥5 were classified as frail. The primary outcomes included the days alive and out of hospital (DAOH) at 90 days following discharge, 30-day and 180-day mortality, length of hospital stay (LOS) and 30-day readmissions. Propensity score matching (PSM) compared clinical outcomes depending on the receipt of HF-specific pharmacotherapy.

Results Of 5734 HF patients admitted over a period of 8 years, 1406 (24.5%) were identified as frail according to the HFRS and were included in this study. Of 1406 frail HF patients, 1025 (72.9%) received HF-specific pharmacotherapy with 381 (27.1%) who did not receive any of these medications. Frail HF patients who did not receive HF-specific pharmacotherapy were significantly older, with higher creatinine and brain natriuretic peptide but with lower haemoglobin and albumin levels (p<0.05) when compared with those frail patients who received HF medications. After PSM frail patients on treatment were more likely to have an increased DAOH (coefficient 16.18, 95% CI 6.32 to 26.04, p=0.001) than those who were not on treatment. Both 30-day (OR 0.30, 95% CI 0.23 to 0.39, p<0.001) and 180-day mortality (OR 0.43, 95% CI 0.33 to 0.54, p<0.001) were significantly lower in frail patients on HF treatment but, there were no significant differences in LOS and 30-day readmissions (p>0.05).

Conclusion This study found an association between the use of HF-specific pharmacotherapy and improved clinical outcomes in frail HF hospitalised patients when compared to those who were not on treatment.

Trial registration number ANZCTR38319575.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This study determined benefits of heart failure-specific pharmacotherapy in frail hospitalised heart failure patients.
⇒ Propensity score matching was used to compare clinical outcomes according to the receipt of treatment in frail heart failure patients.
⇒ This study used the days alive and out of hospital as a primary outcome which considers not only mortality but also hospitalisations for heart failure.
⇒ Some confounders could have been missed due to the observational design of this study.
⇒ The severity of heart failure based on ejection fraction was not available due to lack of echocardiogram results.

INTRODUCTION

Heart failure (HF) is commonly associated with advancing age, with a prevalence of 6% in individuals between 65 and 79 years and up to 14% in those over the age of 80 years.1 The annual rates of acute decompensated HF nearly triples in individuals over the age of 75 years when compared with those between 55 and 64 years, irrespective of factors such as sex and race.1 Studies2 3 suggest that 15%–20% of the HF patients who are discharged alive die within 90 days of hospitalisation. HF rarely occurs in isolation in older adults and usually there is complex interplay of other factors such as non-cardiovascular comorbidities, impaired physical and cognitive function, and social and environmental factors, all of which also contribute to frailty.4 Frailty, defined as a biologic syndrome with impaired physiological reserves that increases susceptibility to stressors5 is common among patients with HF. A recent meta-analysis6 which included 26 studies and 6896 HF patients found that the prevalence of frailty ranged from 43% with the use of physical frailty measures to 47% with multidimensional frailty measures.

Among older frail HF patients there is often an uncertainty whether to prescribe guideline directed pharmacotherapy given the
risks associated with polypharmacy along with concerns regarding adherence to treatment because studies suggest that up to 55% of patients are non-compliant with treatment. In addition, despite a high prevalence of HF in older individuals, there is a dearth of research specifically targeting older frail patients. Evidence indicates that 30% of HF clinical trials have excluded older patients, and the representation in these trials of patients who were older than 80 years of age was only 15%. In addition, a number of HF trials have used indirect criteria such as the number of comorbidities, presence of polypharmacy and a limited life expectancy as reasons to exclude older frail patients. Thus, the older HF patients commonly seen in clinical practice have a limited representation in clinical trials. This poses a significant challenge for the treating clinicians because of lack of information about the efficacy and tolerance of HF-specific interventions in this population. Despite these findings, guidelines still recommend targeted therapy for HF irrespective of age or comorbidities.

We conducted a retrospective study to determine the impact of HF-specific medications (beta blockers, ACE inhibitors (ACEi)/angiotensin receptor blockers (ARBs) and mineralocorticoid receptor antagonist (MRA)) on clinical outcomes of frail patients who were hospitalised with HF. The primary outcomes for this study were the days alive and out of hospital (DAOH) at 90 days following hospital discharge hospital, 30-day and 180-day mortality, and 30-day readmissions and the secondary outcomes included inhospital mortality and hospital length of stay (LOS).

MATERIALS AND METHODS

We included data of all frail patients ≥18 years of age who were hospitalised with HF over a period of 8 years at two tertiary teaching hospitals, Flinders Medical Centre and Royal Adelaide Hospital in Adelaide, Australia. We identified all adult hospital admissions, between 1 January 2013 and 31 December 2020, with a primary diagnosis of HF by using the International Classification of Diseases 10th Revision Australian Modification (ICD-10-AM) code 150, which has been previously used to define HF. In cases where patients had multiple presentations for HF during the study period, then only the first admission was included. The study was retrospective and the data were obtained from the hospitals' electronic medical records of our central computer database. The data of all HF patients who were referred from the emergency department for a medical admission were included in this study. The data were collected independently by one of the researchers and was verified for accuracy by a second researcher. In case of any discrepancy, electronic data were verified manually by extraction of patients’ case notes.

The frailty status of patients was determined by use of the Hospital Frailty Risk Score (HFRS), which was calculated according to the criteria defined by Gilbert et al. The HFRS was calculated from the data obtained from our central computer database which contains information about patients’ previous presentations to hospital. We used patient’s records over a 2-year period to calculate the HFRS. HFRS is based on administrative data by allocating point values for any of 109 select ICD codes as defined in the original publication. These codes include diagnoses such as falls, osteoporosis, spinal compression fractures, blindness, skin ulcers, delirium/dementia, Parkinson’s disease, urinary incontinence, urinary tract infections, disorders of electrolytes, drugs/alcohol abuse and sequelae of stroke such as hemiplegia and dysphagia. None of the ICD-10 codes used for the generation of the HFRS score is for HF, atrial fibrillation, or coronary artery disease (CAD). Higher HFRS scores indicate a greater severity of frailty and, we classified patients with a HFRS score ≥5 as frail and those with HFRS scores of <5 as non-frail as has been done in previous studies.

We determined medications prescribed to patients at discharge from hospital from our pharmacy database. This database contains comprehensive information about medications which patients are on prior to their hospital presentation including any new medications prescribed during the course of their hospitalisation and at the time of hospital discharge. However, we were unable to determine the doses or durations of prescribed medications. In particular, we determined whether patients received any or all of the HF-specific medications (beta blockers, ACEi/ARBs and MRA) in addition to other medications such as aspirin, warfarin, direct acting oral anticoagulants (DOACs), statins, ivabradine and digoxin. Over the course of the study, newer medications such as sodium-glucose transport protein 2 (SGLT2) inhibitors and sacubitril/valsartan were also available for management of HF. We determined the socioeconomic status of the patients by using the index of relative socioeconomic disadvantage (IRSD). The comorbidity risk was determined by use of the Charlson comorbidity index (CCI) and nutritional status was assessed by use of the Malnutrition Universal Screening Tool (MUST). The severity of HF was assessed by use of the N-terminal probranatriuretic peptide (NT-proBNP) levels. In addition, we determined common investigations performed during hospital admission: haemoglobin, C reactive protein (CRP), albumin, creatinine and troponin levels.

The outcomes examined included: DAOH at 90 days of discharge from hospital, LOS, inhospital mortality, 30-day mortality (from day of index admission), 180-day mortality and 30-day readmissions, and placement in a nursing home. The outcome data for this study were recorded from our central computer database, which contains information about mortality including deaths outside hospital, admissions to other hospitals in the state of South Australia including patients’ LOS, readmissions and placement in a nursing home.

Sharma Y, et al. BMJ Open 2022;12:e059905. doi:10.1136/bmjopen-2021-059905
Patient and public involvement statement

This study was retrospective and it was not possible to involve patients in the design or conduct of this study.

Statistics

Data were assessed for normality by visual inspection of the histograms. Continuous variables were assessed by use of the t-tests or rank sum tests, as appropriate while categorical variables were assessed by $\chi^2$ statistics.

Propensity score methods

We used propensity score matching to control for any potential confounding factors between the two cohorts of frail patients: frail patients who received HF-specific pharmacotherapy and those who did not receive treatment. We used propensity score matching to account for the fact that patients’ baseline health, comorbidities and frailty status may account for their probability of receiving HF-specific pharmacotherapy. To create propensity scores, we first used multivariable logistic regression model with receipt of HF-specific pharmacotherapy as the outcome variable and the potential confounders as the explanatory variables. Seventeen confounding variables which were hypothesised to be associated both with the exposure and the outcomes included: age, age $\geq$65 years, sex, HFRS, MUST score, IRSD, CCI, haemoglobin, CRP, creatinine, BNP, troponins, albumin levels and the use of aspirin, warfarin, DOACs and statins. We did not analyse newer HF medications (SGLT2 inhibitors and Sacubitril-Valsartan) which were available later in course of the study because very few HF patients received this treatment. The overlap of distribution of propensity scores between the two groups was checked by visual inspection of the histogram. We used kernel matching to compare propensity scores between the two treatment groups. A kernel bandwidth of 0.06 as suggested by Heckman et al was employed to optimise trade-off between variance and bias. After kernel matching, the balance of covariates was assessed using the standardised mean differences (SMR), with $\geq$10% standard mean difference considered as significant between the two groups. Kernel densities were plotted to examine the differences in continuous variables across matched treatment and comparison groups to determine similarity. In the matched cohort, outcomes were compared between the two groups of patients by assessment of the average treatment effect.

Sensitivity analyses were performed by use of the average treatment effect on the treated (ATET) to assess the robustness of results generated by the use of propensity score matching and coefficients with robust standard errors and 95% CIs were generated. All tests were two sided and a p<0.05 was regarded as statistically significant. All statistical analyses were performed by use of STATA software V.17.0 (StataCorp).

RESULTS

There were 8050 admissions with HF between 1 January 2013 and 31 December 2020. After omitting multiple admissions and missing data, 5734 patients remained in the dataset, of whom, 1406 (24.5%) patients were identified as frail according to the HFRS and were included in this study (figure 1). Frail patients were more likely to be older, with a poor nutritional status, a higher CCI and creatinine levels and were more likely to belong to a lower socioeconomic status than non-frail patients (p<0.05). However, there was no difference in relation to gender, severity of HF as determined by the NT-proBNP and troponin levels between the frail and non-frail group.

Overall, 4576 (79.8%) patients received one or more medications defined as HF-specific pharmacotherapy. Baseline characteristics differed among patients who received HF-specific pharmacotherapy compared with those who did not receive these medications (table 1). Patients who received HF-specific pharmacotherapy were more likely to be younger, with a lower creatinine, BNP and CRP levels and higher haemoglobin and albumin levels but there was no difference with regard to their nutritional or socioeconomic status (table 1). When compared with non-frail patients, frail patients were significantly less likely to be prescribed HF-specific pharmacotherapy (72.9% vs 82.1%, p<0.001). In terms of individual HF-specific medications, more non-frail patients were on beta blockers (66.9% vs 58.7%, p<0.001), ACEi (43.4% vs 31.6%, p<0.001) and MRA (37.9% vs 32.7%, p<0.001) but not ARBs (13.8% vs 12.4%, p=0.178) when compared with frail patients (figure 2).

Of 1406 frail HF patients, 1025 (72.9%) received HF-specific pharmacotherapy compared with 381 (27.1%) who did not receive any one or more these medications (figure 1). Frail HF patients who did not receive HF-specific pharmacotherapy were significantly older, with higher creatinine and BNP levels but had lower haemoglobin and albumin levels (p<0.05) when...
compared with those frail patients who received treatment (table 1).

**Propensity score matching**

The propensity score model which was built with the use of seventeen variables after multivariable logistic regression model in frail HF patients, included 930 observations in the treated and control group and were well matched with an SMR of <10% (figure 3, table 2).

**Clinical outcomes in frail patients depending on receipt of HF-specific pharmacotherapy**

The mean (SD) DAOH was significantly increased in frail HF patients who received HF-specific pharmacotherapy compared with those who did not receive treatment (67.7 (33.1) days vs 47.1 (40.9) days, p<0.001) and these patients had 4.9-fold higher odds of having an increased DAOH compared with those who did not receive treatment (OR 4.90, 95% CI 3.64 to 6.58, p<0.001) (table 3).

| Characteristic                  | Not frail and received heart failure-specific pharmacotherapy | Not frail and no heart failure-specific pharmacotherapy | P value | Frail and received heart failure-specific pharmacotherapy | Frail and no heart failure-specific pharmacotherapy | P value |
|--------------------------------|-------------------------------------------------------------|--------------------------------------------------------|---------|----------------------------------------------------------|-----------------------------------------------------|---------|
| **Total**                      | n=3551                                                      | n=777                                                  | <0.001  | n=1025                                                   | n=381                                               | 0.025   |
| Age years mean (SD)            | 74.4 (14.4)                                                 | 78.6 (13.5)                                            | <0.001  | 79.2 (12.5)                                              | 80.8 (12.6)                                         | 0.025   |
| Age ≥65 years n (%)            | 2776 (78.2)                                                 | 666 (85.7)                                             | <0.001  | 902 (88)                                                 | 344 (90.3)                                          | 0.230   |
| Sex male n (%)                 | 1895 (53.4)                                                 | 371 (47.8)                                             | 0.005   | 513 (50.1)                                               | 195 (51.2)                                          | 0.706   |
| Charlson index mean (SD)       | 2.1 (1.5)                                                   | 2.2 (1.7)                                              | 0.199   | 3.3 (1.9)                                                | 3.3 (2.1)                                           | 0.875   |
| IRSD mean (SD)                 | 5.4 (2.6)                                                   | 5.4 (2.7)                                              | 0.517   | 5.6 (2.7)                                                | 5.6 (2.8)                                           | 0.903   |
| Haemoglobin g/L mean (SD)      | 114.1 (63.9)                                                | 119.5 (81.3)                                           | 0.047   | 151.4 (84.2)                                             | 166.9 (108.9)                                       | 0.005   |
| NT-proBNP mean ng/L (SD)       | 1451.2 (4427.6)                                             | 1923.7 (4654.2)                                        | 0.002   | 2552.7 (6545.7)                                          | 4465.0 (9311.8)                                     | <0.001  |
| Troponin ng/L mean (SD)        | 0.9 (15.7)                                                  | 4.7 (58.5)                                             | 0.002   | 0.7 (9.2)                                                | 1.2 (11.4)                                          | 0.416   |
| CRP mg/L mean (SD)             | 21.8 (32.5)                                                 | 24.5 (36.3)                                            | 0.092   | 33.9 (48.3)                                              | 43.3 (58.9)                                         | 0.006   |
| Albumin g/L mean (SD)          | 34.6 (4.9)                                                  | 33.8 (4.8)                                             | 0.002   | 32.9 (5.1)                                               | 31.5 (5.8)                                          | <0.001  |
| HFRS mean (SD)                 | 1.5 (1.5)                                                   | 1.7 (1.6)                                              | 0.006   | 8.5 (3.4)                                                | 9.1 (3.5)                                           | 0.004   |
| MUST mean (SD)                 | 0.5 (0.9)                                                   | 0.4 (0.8)                                              | 0.437   | 0.7 (1.1)                                                | 0.9 (1.3)                                           | 0.145   |
| Aspirin n (%)                  | 1496 (42.1)                                                 | 116 (14.9)                                             | <0.001  | 399 (38.9)                                               | 50 (13.1)                                           | <0.001  |
| Warfarin n (%)                 | 755 (21.3)                                                  | 51 (6.6)                                               | <0.001  | 274 (26.7)                                               | 36 (9.5)                                            | <0.001  |
| DOACs n (%)                    | 770 (21.7)                                                  | 45 (5.8)                                               | <0.001  | 212 (20.7)                                               | 11 (2.9)                                            | <0.001  |
| Statins n (%)                  | 2026 (57.1)                                                 | 125 (16.1)                                             | <0.001  | 517 (50.4)                                               | 60 (15.8)                                           | <0.001  |
| ARNI n (%)                     | 75 (2.1)                                                    | 0                                                      | <0.001  | 22 (2.2)                                                 | 0                                                   | 0.004   |
| SGLT2 inhibitors, n (%)         | 70 (1.9)                                                    | 2 (0.3)                                                | 0.001   | 19 (1.9)                                                 | 1 (0.3)                                             | 0.025   |
| Digoxin n (%)                  | 587 (16.5)                                                  | 36 (4.6)                                               | <0.001  | 221 (21.6)                                               | 22 (5.8)                                            | <0.001  |
| Ivabradine n (%)               | 85 (2.4)                                                    | 5 (0.6)                                                | 0.002   | 23 (2.2)                                                 | 2 (0.5)                                             | 0.030   |

ARNI, angiotensin receptor-neprilysin inhibitor; CRP, C reactive protein; DOACs, direct oral anticoagulants; HFRS, hospital frailty risk score; IRSD, Index of Relative Socioeconomic Disadvantage; MUST, malnutrition universal screening tool; NT-proBNP, N-terminal probrain natriuretic peptide; SGLT2, sodium glucose co-transporter two inhibitor.
The differences in the DAOH90 remained statistically significant (p<0.05) irrespective of gender, age (<65 years or ≥65 years) or the duration of study (patients admitted before or after 31 December 2016). After PS matching, the DAOH remained significantly increased in frail HF patients who received HF-specific pharmacotherapy compared with those who did not receive treatment (coefficient 16.18, robust SE 5.03, 95% CI 6.32 to 26.04, p=0.001) (table 4). The inhospital, 30-day and 180-day mortality rates were significantly lower among frail HF patients who received HF-specific pharmacotherapy when compared with those frail patients who did not receive treatment (p<0.05) (tables 3 and 4). At 30 days following hospital discharge, the odds of death were 70% lower among those frail patients who received HF-specific pharmacotherapy compared with those who were not on treatment (OR 0.30, 95% CI 0.23 to 0.39, p<0.001). The number needed to treat (NNT) to prevent one inhospital death among frail patients was 4, and NNT needed to prevent one death at 30 days of discharge was 4.2. However, there were no significant differences in LOS or 30-day readmissions between frail patients who received or did not receive HF-specific pharmacotherapy (p>0.05) (tables 3 and 4).

Sensitivity analysis
Sensitivity analyses with determination of the ATET confirmed that DAOH at 90 days following discharge were significantly increased and inhospital, 30-day and 180-day mortality were significantly reduced in frail patients who received HF-specific pharmacotherapy (p<0.05). However, there were no significant differences in 30-day readmissions and LOS (p>0.05) in frail patients who received or did not receive HF-specific pharmacotherapy (table 5).

DISCUSSION
The results of this study indicate that almost a quarter of patients who were hospitalised with HF were frail. Overall, patients who received HF-specific pharmacotherapy were more likely to be younger with lower creatinine and BNP levels but with higher haemoglobin and CRP levels. Frail patients as defined by the HFRS were significantly less likely to be on HF-specific pharmacotherapy than the non-frail counterparts. After propensity score matching, an increased DAOH was more likely to be associated with prescription of HF-specific pharmacotherapy in frail HF patients. In addition, prescription of HF-specific pharmacotherapy in frail HF patients was more likely to be associated with a reduction in inhospital, 30-day and 180-day...
mortality but not with a reduction in LOS or 30-day readmissions.

The findings of our study are significant because there is a marked discrepancy between patients evaluated in most HF clinical trials and the spectrum of patients seen in clinical practice especially in terms of age and frailty status. Patients included in the HF clinical trials are more likely to be younger males, with a significantly less comorbidity and on fewer medications than those HF patients who are seen in clinical practice. This contrasts to a real-world scenario where HF patients are often older with a higher comorbidity burden and on polypharmacy.

Our study suggests that frail patients were less likely to receive HF-specific medications and confirm the results of a recent study, which included 291 HF patients with reduced ejection fraction attending a community clinic, and this study also found that compared with non-frail patients, frail patients were less likely to be prescribed the three major classes of HF-specific medications (ACEi/ARA, beta blockers and MRA) and this study also found that those who did receive treatment were more likely to receive suboptimal doses. The potential reasons for less prescription of HF-specific medications in frail patients could be related to a lack of clear guidelines on management of frail HF patients, the presence of comorbidities such as renal failure or asthma, which may be a contraindication to prescription of ACEi/ARBs and beta blockers, patients’ preferences and concerns about side effects of medications (such as hypotension and fatigue) or a lack of compliance with medications in this population.

Our study found that HF-specific pharmacotherapy was associated with improvement in clinical outcomes such as the DAOH and mortality among frail patients. However, a major limitation of our study is that we do not have echocardiogram data and thus are unable to differentiate patients based on their ejection fraction. HF with preserved ejection fraction (HFpEF) is commonly associated with comorbidities such as hypertension, atrial fibrillation, CAD, obesity, anaemia, diabetes, chronic kidney disease and sleep-disordered breathing. The above-mentioned comorbidities are also associated with frailty.

Although the use of some medications such as MRA and, more recently, SGLT2 inhibitors reduce the risk of HF hospitalisation and improve quality of life, there is no clear evidence that they reduce mortality. In addition, very few clinical trials have included frail older patients who are more likely to have comorbidities associated with HFpEF. The SENIORS trial found that Nebivolol reduced mortality and hospital admissions in older HF patients, while another study in older frail patients with myocardial infarction found that use of beta blockers was associated with a reduction in hospital admissions for HF. Evidence also suggests that beta blocker therapy in patients with HFpEF is associated with an improvement in echocardiogram parameters and guidelines suggest use of these agents as a heart rate lowering therapy, despite

| Table 3 | Clinical outcomes in frail depending on use of heart failure-specific pharmacotherapy |
|---------|--------------------------------------------------------------------------------------------|
| Outcome variable | No heart failure pharmacotherapy | Received heart failure pharmacotherapy | OR | 95% CI | P value |
| DAOH90 mean (SD) | n=381 | n=1025 | 4.90 | 3.64 to 6.59 | <0.001 |
| Inhospital deaths n (%) | 131 (34.4) | 96 (9.4) | 0.20 | 0.15 to 0.27 | <0.001 |
| 30-day mortality n (%) overall | 161 (42.3) | 185 (18.1) | 0.30 | 0.23 to 0.39 | <0.001 |
| 180-day mortality n (%) overall | 202 (53.0) | 335 (27.2) | 0.43 | 0.33 to 0.54 | <0.001 |
| LOS* median (IQR) overall | 4.8 (2.8, 7.8) | 4.5 (2.3, 8.3) | 0.99 | 0.95 to 1.03 | 0.797 |
| 30-day readmissions n (%) overall | 70 (18.4) | 213 (20.8) | 1.16 | 0.86 to 1.57 | 0.317 |

*LOS adjusted for inhospital deaths. DAOH90, days alive and out of hospital at 90 days of discharge; LOS, length of hospital stay.

| Table 4 | Outcomes in frail heart failure patients after propensity score matching depending on prescription of heart failure-specific pharmacotherapy |
|---------|-------------------------------------------------------------------------------------------------------------------------------------|
| Outcome | Coefficient | Robust SE | 95% CI | P value |
| DAOH90 | 16.18 | 5.03 | 6.32 to 26.04 | 0.001 |
| Inhospital mortality | −0.24 | 0.05 | −0.34 to −0.13 | <0.001 |
| 30-day mortality | −0.19 | 0.06 | −0.30 to −0.09 | <0.001 |
| 180-day mortality | −0.14 | 0.07 | −0.28 to −0.01 | 0.038 |
| 30-day readmissions | 0.04 | 0.04 | −0.04 to 0.12 | 0.334 |
| LOS | 0.06 | 0.76 | −1.43 to 1.55 | 0.938 |

DAOH90, days alive and out of hospital at 90 days following discharge; LOS, length of hospital stay.
Table 5  Outcomes in frail heart failure patients using the average treatment effect on the treated depending on prescription of heart failure-specific pharmacotherapy in non-frail and frail patients

| Outcome               | Coefficient | Robust SE | 95% CI      | P value |
|-----------------------|-------------|-----------|-------------|---------|
| DAOH90                | 15.40       | 5.81      | 4.01 to 26.79 | 0.008   |
| Inhospital mortality  | -0.24       | 0.06      | -0.36 to -0.11 | <0.001 |
| 30-day mortality      | -0.18       | 0.06      | -0.30 to -0.06 | 0.004   |
| 180-day mortality     | -0.15       | 0.08      | -0.31 to -0.01 | 0.041   |
| 30-day readmissions   | 0.06        | 0.05      | -0.03 to 0.16 | 0.188   |
| LOS                   | 0.03        | 0.86      | -1.67 to 1.73 | 0.976   |

DAOH90, days alive and out of hospital at 90 days following discharge; LOS, length of hospital stay.

a lack of proven reduction in mortality. Two recent HF clinical trials the PARADIGM HF and the DAPA HF, which investigated the role of Sacubitril/Valsartan and Dapagliflozin in HF, although, have enrolled only a minority of older patients (>75 years) (19% and 24%, respectively) have found that there was no evidence of lesser benefits with these agents in older patients. In an older frail population, the risk of dying from a natural cause or a non-cardiovascular condition may be a competing risk factor for potential beneficial effects of a specific treatment. It is possible that there is a threshold for biological age rather than chronological age beyond which the absolute benefits of HF-specific treatments will be difficult to prove. As the prevalence of frailty is expected to increase with an ageing population, the management of frail HF patients will remain a significant medical challenge. The results of our study are hypothesis generating in that there may be potential benefits of prescribing HF-specific pharmacotherapy in some frail patients who are deemed suitable and such an action may potentially reduce adverse clinical outcomes. However, further studies in the frail older population are needed to verify our findings. Aggressive HF treatment may be less important in some patients who are severely frail with contraindications to treatment, who may need interventions to address frailty rather than HF. There is a need for a holistic approach when addressing issues associated with the management of frail HF patients and issues such as cognitive impairment, malnutrition and depression needs an early assessment and remedial measures.

This study has several limitations. Due to its observational design, there is a possibility that a number of confounding factors, which could have influenced the clinical outcomes among frail patients have not been accounted for, so results should be interpreted with caution. It is possible that in some patients, HF-specific medications were stopped during the index admission due to reasons such as palliation which could have potentially confounded the outcomes. We were unable to secure echocardiogram data, and thus were unable to determine the ejection fraction, however, the severity of HF was judged from BNP levels. Over the course of study, newer medications for HF were available which could have influenced clinical outcomes. Unfortunately, we were unable to account for these medications because very few frail patients received these medications.

CONCLUSION

Frail patients were less likely to receive HF-specific pharmacotherapy than non-frail counterparts. This study also found an association between the use of HF-specific pharmacotherapy and improved clinical outcomes measured in terms of increased number of DAOH and reduced 30-day and 180-day mortality in frail patients. There is a need for further studies to confirm our findings.

REFERENCES

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation 2017;135:e146–603.
2. Chen Y, Lawrence J, Stockbridge N. Days alive out of hospital in heart failure: insights from the PARADIGM–HF and CHARMI trials. Am Heart J 2021;241:108–19.
3. Anti CA, Cleland JGF, Pocock SJ, et al. Days alive and out of hospital and the patient journey in patients with heart failure.
insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. *Am Heart J* 2011;162:900–6.

4. Gorodeski EZ, Goyal P, Hummel SL, et al. Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future. *J Am Coll Cardiol* 2016;71:1921–36.

5. Abellan van Kan G, Rolland YM, Morley JE, et al. Frailty: toward a clinical definition. *J Am Med Dir Assoc* 2008;9:71–2.

6. Denfeld OE, Winters-Stone K, Mudd JO, et al. The prevalence of frailty in heart failure: a systematic review and meta-analysis. *Int J Cardiol* 2017;236:283–9.

7. Leventhal MJ, Riegel B, Carlson B, et al. Negotiating compliance in heart failure: remaining issues and questions. *Eur J Cardiovasc Nurs* 2005;4:298–307.

8. Sze S, Pellicori P, Zhang J, et al. Effect of frailty on treatment, hospitalisation and death in patients with chronic heart failure. *Clin Res Cardiol* 2021;110:1249–58.

9. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. *Arch Intern Med* 2002;162:1682–8.

10. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. *Am Heart J* 2003;146:250–7.

11. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. *Arch Intern Med* 2011;171:550–6.

12. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail* 2017;23:628–51.

13. Joshy G, Korda RJ, Abhayaratna WP, et al. Categorising major cardiovascular disease hospitalisations from routinely collected data. *Public Health Res Pract* 2015;25:e2531532.

14. Gilbert T, Neuberger J, Kaindlir J, et al. Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic Hospital records: an observational study. *Lancet* 2018;391:1775–82.

15. McAlister FA, Sauv A, Ezekowitz JA, et al. The hospital frailty risk score in patients with heart failure is strongly associated with outcomes but less so with pharmacotherapy. *J Intern Med* 2020;287:322–32.

16. Adams RJ, Howard N, Tucker G, et al. Effects of area deprivation on health risks and outcomes: a multilevel, cross-sectional, Australian population study. *Int J Public Health* 2009;54:183–92.

17. Frenkel WJ, Jongerius EJ, Mandjes-van Uitert MJ, et al. Validation of the Charlson comorbidity index in acutely hospitalized elderly adults: a prospective cohort study. *J Am Geriatr Soc* 2014;62:342–6.

18. Sharma Y, Thompson C, Kaambwa B, et al. Validity of the malnutrition universal screening tool (mus) in Australian hospitalized acutely unwell elderly patients. *Asia Pac J Clin Nutr* 2017;26:994–1000.

19. Mueller C, McDonald K, de Boer RA, et al. Heart failure association of the European Society of cardiology practical guidance on the use of natriuretic peptide concentrations. *Eur J Heart Fail* 2019;21:715–31.

20. Heckman JJ, Ichimura H, Todd PE. Matching as an Econometric evaluation estimator: evidence from evaluating a job training programme. *Rev Econ Stud* 1997;64:605–54.

21. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;28:3083–107.

22. Badano LP, Di Lenarda A, Bellotti P, et al. Patients with chronic heart failure encountered in daily clinical practice are different from the “typical” patient enrolled in therapeutic trials. *Ital Heart J* 2003;4:84–91.

23. Baxter AJ, Spensley A, Hildreth A, et al. Beta blockers in older persons with heart failure: tolerability and impact on quality of life. *Heart* 2002;88:611–4.

24. Dulin BR, Krum H. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. *Curr Opin Cardiol* 2006;21:393–9.

25. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (seniors). *Eur Heart J* 2005;26:215–25.

26. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. *Lancet* 2000;356:639–44.

27. Bjerregaard A, Andersson B, Edner M, et al. Effect of candesartan on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). *Eur J Heart Fail* 2004;6:453–61.

28. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;371:993–1004.

29. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019;381:1995–2008.

30. Sze S, Zhang J, Pellicori P, et al. Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction. *Clin Res Cardiol* 2017;106:533–41.